Background. Patients with humoral immune deficiency are susceptible to invasive pneumococcal disease (IPD). This study estimates the prevalence of underlying hypogammaglobulinemia in admitted IPD cases and examines whether IPD cases had received preventative treatment.
Streptococcus pneumoniae is the most common cause of community-acquired pneumonia (CAP) worldwide and accounts for 27.3% of CAP cases [1] . Person-to-person transmission of S. pneumoniae requires inhalation of inoculated respiratory droplets with subsequent colonization of the nasopharyngeal epithelium [1] .
More than 90 different capsular polysaccharide serotypes of S. pneumoniae have been identified. The majority of disease is caused by a relatively small subset of serotypes, on which the clinical effectiveness of pneumococcal vaccination is based [2, 3] . Vaccination of infants and young children with pneumococcal conjugate vaccine has resulted in the significant decrease in nasal carriage rates and pneumococcal disease in all age groups [4] . However, invasive pneumococcal disease (IPD) remains a leading cause of morbidity and mortality. In the United States, there were 33 900 cases (10.7/100 000 population) and an estimate of 3700 deaths (1.2/100 000 population) attributed to pneumococcal meningitis and bacteremia in 2013 [5] . Canada identified 2473 IPD cases (8.9/100 000) in 2014 [6] . The case fatality rate is 5.6% among people with no risk factors and ranges from 15% to 30% among people with coexisting chronic disease and advanced age [7] .
Host immunity against pneumococcus is generated via production of serotype-specific opsonizing antibodies and complement-mediated phagocytosis. Patients with humoral immune deficiency including specific antibody deficiencies are susceptible to encapsulated bacterial organisms such as S. pneumoniae [5, 8, 9] . Previous studies showed that 18% to 37.8% of patients with IPD have underlying primary or secondary immunoglobulin deficiency or hypogammaglobulinemia [10] [11] [12] . If the diagnosis is made prior to severe infections and invasive disease, patients with antibody deficiency may benefit from antibiotic prophylaxis or immunoglobulin replacement therapy [9, 13, 14] .
Hypogammaglobulinemia is defined by a quantitative decrease in immunoglobulins, caused by primary (congenital) or secondary (acquired) disorders [15] . Primary disorders such as congenital B-cell disorders or combined immune deficiencies are inherited or due to spontaneous mutation [15] . Secondary hypogammaglobulinemias are the result of reduced immunoglobulin production, or clearance associated with other diseases and medical treatments [15] . Although hypogammaglobulinemia is defined by decreased serum levels of total immunoglobulin (Ig) or immunoglobulin G (IgG), isolated immunoglobulin A (IgA) deficiency has also been associated with an increased susceptibility to pneumonia and recurrent respiratory infections [9, 16] .
Diseases such as chronic lymphocytic leukemia (CLL), multiple myeloma (MM), B-cell lymphoma, primary amyloidosis, and monoclonal gammopathy of unknown significance can affect immunoglobulin production [17] . Between 27% and 52% of patients with CLL are diagnosed with hypogammaglobulinemia, and the prevalence can be as high as 85% depending on the stage of the disease [17] . Hypogammaglobulinemia was reported in 8% of newly diagnosed MM patients [18] . Both nephrotic syndrome and protein-losing enteropathy can manifest with hypogammaglobulinemia, predominantly affecting IgG levels [15] . Medications for treating underlying diseases, and patient factors, such as current smoking status and chronic lung disease, have been independently linked to immune deficiency and concomitant infection risk [17, 19] .
In this study, we sought to determine prevalence of hypogammaglobulinemia in IPD cases at our center and to examine whether cases had documentation of past or planned pneumococcal vaccination, smoking cessation treatments, and either antibiotic or immunoglobulin prophylaxis.
METHODS
We retrospectively reviewed the charts of patients diagnosed with IPD at The Ottawa Hospital (TOH), Ontario, Canada between January 2013 and December 2015. IPD was defined by the isolation of S. pneumoniae from blood or cerebrospinal fluid (CSF). Where possible, we collected the following information: age, sex, comorbidities, smoking status, mortality (allcause, in-hospital, and 30-day), pneumococcal vaccine status, S. pneumoniae serotype of the presenting infection, and serum immunoglobulin levels before the current infection. Where not provided, we prospectively requested immunoglobulin levels at an outpatient visit, or from the patients' primary care provider following hospital discharge.
S. pneumoniae serotypes were classified as vaccine serotypes if they were contained in the 23-valent pneumococcal polysaccharide vaccine (PPSV23; serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) or the 13-valent pneumococcal conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) [20] .
We defined hypogammaglobulinemia as IgG levels <7g/L as measured by Ig quantitative nephelometry or gamma globulin <6 g/L by serum protein electrophoresis (SPEP), measured either before IPD, during hospitalization with confirmation in convalescence if possible, or in convalescence. In cases of monoclonal gammopathy, we used gamma globulin levels measured by SPEP instead of IgG levels measured by nephelometry because the gamma globulin levels reported by SPEP are polyclonal gamma globulin levels excluding monoclonal values. We also reported cases with low IgA level without hypogammaglobulinemia, which is different from isolated IgA deficiency [9] .
Continuous variables were described using means, standard deviations (SD), and ranges. Categorical variables were described using proportions and frequencies. This study was approved by the Ottawa Hospital Research Ethics Board (OHREB 20140872-01H).
RESULTS

Demographic and Clinical Characteristics of the Study Population
We identified 134 IPD cases in 133 patients (Table 1) . Of the 134 isolates, 132 were collected from blood, whereas 2 were isolated from CSF. Most (85.8%) isolates were associated with concomitant pneumonia. The male-to-female ratio was 0.9 (63 males and 70 females). Mean age at the time of the first IPD was 63 years (SD = 15.6). Approximately 31.3% of patients were active smokers. Comorbidities are summarized within Table 1 and included 24 cases of solid malignancy, 18 cases of hematological malignancy, and 30 cases of chronic lung disease. Allcause mortality was 22.6% over a mean follow-up time of 362, SD = 345 days. In-hospital and 30-day mortality were 12% and 11.3%, respectively.
Hypogammaglobulinemia and Low Immunoglobulin A Level Without Hypogammaglobulinemia
Of 133 patients, 57 (42.9%) had Ig levels measured. Thirty-eight (28.6%) patients had Ig levels measured after IPD diagnosis (mean = 383, SD = 340 days), whereas 19 (14.3%) had Ig levels measured prior to IPD. Eight patients had Ig levels measured within 30 days of IPD (range 1-27 days). Seventy-six (57.1%) patients did not have their Ig levels measured or recorded due to death (n = 26) or loss to follow-up (n = 50).
Of the 57 patients who had their Ig levels measured, 18 (31.6%) were found to have hypogammaglobulinemia (Table 2) . One out-of-province patient had IgG levels measured within 30 days of IPD (IgG level 2.5 g/L) without convalescent confirmation. Mean IgG level of these 18 patients was 3.33, SD = 1.66 g/L. Comorbidities included hematological malignancy (n = 13), solid tumor (n = 1), chronic obstructive pulmonary disease (COPD; n = 1), chronic hepatitis C infection (n = 1), diabetes (n = 1), and rheumatoid arthritis (n = 1). Mean Ig level in the 13 patients with hematological malignancy was 3.23, SD = 1.51 g/L, whereas in the 5 patients with other comorbidities mean Ig level was 3.3, SD = 1.74 g/L. In sum, 10 patients were known to have hypogammaglobulinemia prior to IPD, and 9 had hematological malignancy.
Furthermore, we identified three individuals (2 men and 1 woman) with low IgA level without hypogammaglobulinemia (Table 3) . 
Pneumococcal Vaccination and Secondary Prevention
Of the total 134 pneumococcal isolates in our study, 129 (96.3%) were serotyped. Ninety-three (72.1%) were vaccine serotypes, and of these, 48 (37.2%) and 93 (72.1%) were PCV13 and PPSV23 vaccine serotypes, respectively. Only 8 (6.0%) patients in the cohort had documentation of prior pneumococcal vaccination, and of them, 3 (37.5%) were infected with nonvaccine serotypes (24F and 38), 2 (25%) were infected with vaccine serotypes (11A and 19F), and 1 (12.5%) was infected with 17F (included in PPSV23, but not PCV13 which is what the patient had received). The remaining 2 isolates were not serotyped. Among the 10 patients known to have hypogammaglobulinemia before their IPD, only 2 (20%) had received pneumococcal vaccination. The serotypes associated with their IPD were not vaccine preventable. There was no in-hospital documentation of smoking cessation treatment or pneumococcal vaccination planning. Only 1 of 10 known hypogammaglobulinemic patients had received antibiotic prophylaxis or immunoglobulin replacement therapy prior to IPD, but this was discontinued 4 months prior to admission for IPD. On IPD admission, 2 out of 10 known hypogammaglobulinemic patients received immunoglobulin replacement therapy, and 1 was offered long-term antibiotic prophylaxis afterward.
DISCUSSION
Hypogammaglobulinemia has been reported in one third of patients with invasive pneumococcal disease [10, 11, 21] . Among IPD patients at TOH, between January 2013 and December 2015, we estimate upper and lower range of prevalence of hypogammaglobulinemia as 31.6% and 13.5%, respectively. This is in keeping with previous reports in other settings [10, 11] . No previously documented hypogammaglobulinemic patients on Ig replacement therapy were among these cases of IPD. Few patients within our study had documentation of past or planned pneumococcal vaccination and none had documentation for smoking cessation.
In sum, 13 of 18 patients (72.2%) who had hematologic malignancy (i.e., CLL, lymphoma, MM) were found to have hypogammaglobulinemia. Hypogammaglobulinemia can be intrinsic in lymphoproliferative diseases, MM, and chemo-immunotherapy regimens [22] , which can be irreversible in some patients. A chart review of all patients with IPD in Alberta, Canada, demonstrated a higher rate of hypogammaglobulinemia in CLL, lymphoma, and MM compared to the general adult population [23] .
All 5 hypogammaglobulinemia patients without a history of hematological malignancy had comorbidities or medications associated with low IgG levels. The presence of multiple risk factors in these patients makes it difficult to attribute a single cause of hypogammaglobulinemia [24, 25] . Chronic lung diseases (COPD and/or asthma) were found to be the most frequent comorbidities of pneumococcal disease with fold-increases of 1.3 to 16.8 compared to others without these comorbidities [26, 27] . The high prevalence of chronic lung disease (22.6%) in our study population reflects prior findings that chronic obstructive pulmonary disorder was an underlying risk factor for pneumococcal pneumonia [28] , and asthma was associated with increased risk of IPD [29] .
About one third of cases were active smokers, which is consistent with the finding that cigarette smoking is the strongest independent risk factor for IPD among immunocompetent, young adults [19] . According to Centers for Disease Control and Prevention unpublished data, reducing the prevalence of cigarette smoking to 15% could reduce the incidence of IPD among young adults by approximately 18%, preventing approximately 4000 cases in the United States annually [19] . In addition, interventions aimed at smoking cessation are highly cost-effective compared with other healthcare programs. In assessment of the cost-benefit value of medical and surgical interventions aimed at preventing certain diseases, smoking cessation following a health provider's advice was ranked 3rd of 21 interventions [30] . Therefore, smoking cessation should be implemented as a part of a patient's management, particularly IPD patients, and physicians should be proactive in motivating and aiding their patients to stop smoking [30] .
The treatment of patients with antibody deficiency includes IgG replacement therapy and supportive care such as antibiotics and pulmonary hygiene measures to improve the mobilization of airway secretions [9] . Randomized controlled studies conducted in the 1980s and 1990s suggest intravenous Ig (IVIg) has a protective role against life-threatening infections and reduces the frequency of recurrent infections in patients with Serum reference ranges: IgG < 6 g/L, IgA < 0.7 g/L, IgM < 0.5 g/L [8] Abbreviations: IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M.
CLL, MM, and secondary hypogammaglobulinemia [22, 31] . Subcutaneous formulations of IgG have been reported to be as efficacious as IVIg in reducing the frequency and severity of respiratory tract infections [32] , and it reduces the cost and inconvenience of hospital-based intravenous administration [31] . In addition, pneumococcal conjugate and polysaccharide vaccines can be used as a preventative measure. Because immunosuppressive therapy in hematological malignancies is likely to suppress the response to vaccination, better responses might be obtained if vaccination is given before therapy, where possible [33, 34] . Vaccination and/or Ig replacement should be considered in hematologic malignancy patients to prevent IPD, although efficacy needs to be studied in the advent of newer chemoimmunotherapies, which can extend lifespan but do not correct, and may increase secondary hypogammaglobulinemia [22, 31, 33] . Antibiotic prophylaxis has been used in addition to IgG replacement to prevent recurrent infection of the upper and lower respiratory tract in patients with primary B-cell defects, but evidence in secondary B-cell defects is lacking [34] . Three of 133 cases had low IgA level without hypogammaglobulinemia. Primary IgA deficiency has been associated with increased susceptibility to pneumonia and recurrent episodes of respiratory infections [9] . IgA deficiency is the most common primary immunodeficiency with an incidence of 1 case per 300 to 700 persons. Yet its genetic inheritance pattern remains unidentified [35] . An increased frequency of secondary IgA deficiency has also been found in autoimmune disorders including arthritis, a lupus-like illness, autoimmune endocrinopathies, chronic active hepatitis, ulcerative colitis, Crohn's disease, a sprue-like disease, and autoimmune hematologic disorder [9] . All of the 3 patients with low IgA level without hypogammaglobulinemia had at least one of the exposures, that is, cirrhosis, systemic lupus erythematosus, and diffuse large B-cell lymphoma (DLBCL) treated with Rituximab (Table 3) . For the last patient with history of resolved DLBCL, IgG, IgA, and IgM levels were all low at the time of Rituximab treatment. However, IgG and IgM recovered but not IgA when we identified patient after an IPD episode. We found that the patient had low IgA level documented as far back as 4 years prior to the diagnosis of lymphoma, which could indicate that this patient perhaps had isolated IgA deficiency.
Within 30 days of diagnosis, 11.3% of IPD patients within our study had died. This is within the expected case fatality rate range, which is reported between 15% to 30% among people with coexisting chronic disease depending on the age groups, and 5.6% among people with no known risk factors [7] .
Although inherently useful, this case series is limited by its retrospective design and incompleteness of testing for hypogammaglobulinemia. Because IPD patients are not routinely screened for immunodeficiency, 57.1% of the study population did not have their level of Ig recorded. The missing data were taken into account by calculating both low and high estimates of hypogammaglobulinemia prevalence. In addition, the threshold levels used to define hypogammaglobulinemia were set at the lower limit of normal of the assay used, whereas the clinical significances of these thresholds remain debatable [8, 10] . Moreover, other laboratory parameter such as pneumococcal antibody titer may be better at assessing humoral immunodeficiency although such testing is not easily accessible [36] . Lastly, immunoglobulin levels in patients with pneumococcal bacteremia have been reported to vary depending on the phases of the disease, such that IgG levels were lower in the acute phase than in the infection-free phase [11] . Therefore, the hypogammaglobulinemia status in this study was determined either before or at least 30 days after the diagnosis of IPD, with only 1 exception. Moreover, lack of documentation and dependence on patient recall may have led to the underestimation of prior vaccinations. This case series does not reflect vaccination and smoking cessation practice in general, as our observations were confined only to IPD cases.
CONCLUSION
In this study, we estimated the prevalence of underlying hypogammaglobulinemia in admitted IPD cases and determined whether these patients received available preventative treatments. Our estimated prevalence of hypogammaglobulinemia is in keeping with previous reports, with many cases associated with underlying hematological malignancy. IPD has high mortality, and most disease is due to vaccine preventable serotypes, underscoring the need for pneumococcal vaccination in at-risk populations. Future studies addressing the efficacy of antibiotic prophylaxis or treatment of hypogammaglobulinemia, and the timing of vaccinations and treatments in patients with hematological malignancies are warranted. The prevalence of immunodeficiencies underlying IPD may warrant routine screening for therapeutic intervention against recurrent infections.
Notes
